BRPI0909691A8 - composto, método para preparar um composto, e, composição farmacêutica - Google Patents

composto, método para preparar um composto, e, composição farmacêutica

Info

Publication number
BRPI0909691A8
BRPI0909691A8 BRPI0909691A BRPI0909691A BRPI0909691A8 BR PI0909691 A8 BRPI0909691 A8 BR PI0909691A8 BR PI0909691 A BRPI0909691 A BR PI0909691A BR PI0909691 A BRPI0909691 A BR PI0909691A BR PI0909691 A8 BRPI0909691 A8 BR PI0909691A8
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0909691A
Other languages
English (en)
Inventor
Hee Park Chan
Hwan Im Jun
Seok Ko Kwang
June Lee Kyoung
Wook Cho Seong
Ok Lee Soon
Young Han Sun
Oh Ahn Sung
Il Lee Won
Original Assignee
C&C Res Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C&C Res Lab filed Critical C&C Res Lab
Publication of BRPI0909691A2 publication Critical patent/BRPI0909691A2/pt
Publication of BRPI0909691A8 publication Critical patent/BRPI0909691A8/pt
Publication of BRPI0909691B1 publication Critical patent/BRPI0909691B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0909691-4A 2008-03-31 2009-03-31 Composto derivado de heterociclo, método para preparar um composto, e, composição farmacêutica BRPI0909691B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2008-0030067 2008-03-31
KR20080030067 2008-03-31
PCT/KR2009/001659 WO2009145456A2 (ko) 2008-03-31 2009-03-31 헤테로사이클 유도체

Publications (3)

Publication Number Publication Date
BRPI0909691A2 BRPI0909691A2 (pt) 2015-08-04
BRPI0909691A8 true BRPI0909691A8 (pt) 2018-01-02
BRPI0909691B1 BRPI0909691B1 (pt) 2021-07-20

Family

ID=41377713

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909691-4A BRPI0909691B1 (pt) 2008-03-31 2009-03-31 Composto derivado de heterociclo, método para preparar um composto, e, composição farmacêutica

Country Status (23)

Country Link
US (1) US8394792B2 (pt)
EP (1) EP2266989B1 (pt)
JP (1) JP5314123B2 (pt)
KR (1) KR101250297B1 (pt)
CN (1) CN102015726B (pt)
AU (1) AU2009252166B9 (pt)
BR (1) BRPI0909691B1 (pt)
CA (1) CA2718709C (pt)
DK (1) DK2266989T3 (pt)
EA (1) EA018521B1 (pt)
ES (1) ES2552311T3 (pt)
HR (1) HRP20151098T1 (pt)
HU (1) HUE026261T2 (pt)
IL (1) IL208203A (pt)
MX (1) MX2010010366A (pt)
MY (1) MY155517A (pt)
NZ (1) NZ587880A (pt)
PL (1) PL2266989T3 (pt)
PT (1) PT2266989E (pt)
SI (1) SI2266989T1 (pt)
TW (2) TWI613203B (pt)
WO (1) WO2009145456A2 (pt)
ZA (1) ZA201006475B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
US20130090334A1 (en) * 2011-10-05 2013-04-11 Hoffmann-La Roche Inc Azabenzoxazine derivatives as crac modulators
MX2014008484A (es) * 2012-01-27 2014-10-14 Teijin Pharma Ltd Agente terapeutico para la diabetes mellitus.
WO2013152308A2 (en) * 2012-04-06 2013-10-10 Deka Products Limited Partnership Water vapor distillation apparatus, method and system
JP5805613B2 (ja) * 2012-11-16 2015-11-04 株式会社神戸製鋼所 改質石炭の製造方法及び改質石炭製造装置
CN103936762B (zh) * 2013-01-17 2016-02-24 上海汇伦生命科技有限公司 吗啉并喹啉类化合物，其制备方法和用途
CN103664764A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-氨基-2-羟基吡啶的制备方法
WO2015106025A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
JP6289619B2 (ja) * 2014-05-13 2018-03-07 帝人ファーマ株式会社 ピリジン誘導体の新規な結晶多形体およびその製造方法
RU2721844C2 (ru) 2014-12-29 2020-05-25 Ниппон Кемифар Ко., Лтд. Ингибиторы urat1
US10029995B2 (en) 2015-09-03 2018-07-24 Forma Therapeutics, Inc. [6,6] fused bicyclic HDAC8 inhibitors
WO2017114352A1 (en) 2015-12-28 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Indolizine derivatives, composition and methods of use
CN108084186B (zh) 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
ES3011357T3 (en) * 2017-05-25 2025-04-07 Jw Pharmaceutical Corp Hydrochloride salt 1.5 hydrate of an heterocyclic derivative compound
CN109111464B (zh) * 2017-06-23 2021-02-26 爱科诺生物医药股份有限公司 一种具有细胞坏死抑制活性的杂环化合物
WO2018237370A1 (en) 2017-06-23 2018-12-27 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
CN111615515B (zh) 2018-01-19 2023-11-24 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用
CN108558906A (zh) * 2018-05-21 2018-09-21 日照市普达医药科技有限公司 一种治疗白内障药物苯并吩噁嗪类化合物及其制备方法
EP3837263B1 (en) 2018-08-13 2024-07-03 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
EP3883936B1 (en) 2018-11-22 2023-07-12 F. Hoffmann-La Roche AG New heterocyclic compounds
CA3138419A1 (en) * 2019-06-17 2020-12-24 Fochon Pharmaceuticals, Ltd. Heterocyclic derivatives and use thereof
IL298645A (en) * 2020-06-04 2023-01-01 Beigene Ltd Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazines as iap antagonists
CN113880774B (zh) * 2020-07-02 2023-12-08 沈阳中化农药化工研发有限公司 一种苯基异恶唑啉类化合物的制备方法
CN111841896B (zh) * 2020-08-06 2022-10-18 武汉工程大学 一种苯并杂环羟肟酸类捕收剂及其制备方法和应用
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN119059989A (zh) * 2023-05-31 2024-12-03 中国药科大学 Urat1抑制剂及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002220389A (ja) * 2001-01-26 2002-08-09 Hokko Chem Ind Co Ltd ピリジルベンズオキサジン誘導体、除草剤および中間体
JP3988832B2 (ja) 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US20060177646A1 (en) * 2005-02-09 2006-08-10 Detlef Burgard Method for producing shatterproof glass panels and casting resin molding
US20070197512A1 (en) 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
EP1996563B1 (en) * 2006-02-13 2012-03-21 F. Hoffmann-La Roche AG Heterobicyclic sulfonamide derivatives for the treatment of diabetes
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US7960377B2 (en) * 2008-03-28 2011-06-14 Cara Therapeutics, Inc. Substituted pyridoxazines

Also Published As

Publication number Publication date
ES2552311T3 (es) 2015-11-27
PT2266989E (pt) 2015-11-23
US8394792B2 (en) 2013-03-12
CA2718709C (en) 2016-08-09
JP5314123B2 (ja) 2013-10-16
IL208203A0 (en) 2010-12-30
KR101250297B1 (ko) 2013-04-03
IL208203A (en) 2016-06-30
CN102015726B (zh) 2014-07-23
TWI500622B (zh) 2015-09-21
CN102015726A (zh) 2011-04-13
HUE026261T2 (en) 2016-06-28
CA2718709A1 (en) 2009-12-03
SI2266989T1 (sl) 2015-12-31
EP2266989B1 (en) 2015-09-02
TWI613203B (zh) 2018-02-01
EA201071144A1 (ru) 2011-06-30
AU2009252166B9 (en) 2014-02-13
HRP20151098T1 (hr) 2016-01-01
TW201522347A (zh) 2015-06-16
US20110028467A1 (en) 2011-02-03
EP2266989A2 (en) 2010-12-29
EA018521B1 (ru) 2013-08-30
AU2009252166B2 (en) 2013-10-10
EP2266989A4 (en) 2011-10-12
BRPI0909691B1 (pt) 2021-07-20
NZ587880A (en) 2012-06-29
ZA201006475B (en) 2011-10-26
BRPI0909691A2 (pt) 2015-08-04
DK2266989T3 (en) 2015-11-23
KR20110005688A (ko) 2011-01-18
AU2009252166A1 (en) 2009-12-03
HK1148283A1 (en) 2011-09-02
JP2011516468A (ja) 2011-05-26
TW201000488A (en) 2010-01-01
PL2266989T3 (pl) 2016-04-29
MY155517A (en) 2015-10-30
WO2009145456A2 (ko) 2009-12-03
WO2009145456A3 (ko) 2010-01-21
MX2010010366A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI0906906A2 (pt) Método para preparar um composto e composto
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI0910072A2 (pt) composto, composição farmaceutic, e, método para prover anestesia a um mamífero.
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0918038A2 (pt) Processos para preparar um composto e um sal, e, composto
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0912194A2 (pt) Adoçante, método para a preparação e adoçante e aplicações do mesmo
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0812999A2 (pt) Método para preparar um composto
BRPI0819568A2 (pt) métodos para a preparação de um composto
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BRPI1011888A2 (pt) processo para preparar um composto, e, composição.
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BRPI0922714A2 (pt) composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica
BRPI0918955A2 (pt) preparação sólida, e, método para estabilizar um composto, e para melhorar a dissoulução de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 498/04

Ipc: C07D 498/04 (2006.01), A61P 13/04 (2006.01), A61P

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.